We hope to complete the final study phase – in which the vaccine is tested on tens of thousands of people – by the end of this year, and we think we will have the vaccine ready in January. Once the vaccine is completed, we will be able to supply a billion doses in the course of 2021.
With the prospect of launching in January 2021, Johnson & Johnson is among the leading COVID-19 vaccine developers. Around a week earlier, both Pfizer (US) and BioNTech (Germany), as well as Moderna (US), reported that their candidate vaccines are performing excellently in their Phase 3 studies. AstraZeneca (UK) and Oxford University also claim to be close to the finalization of their respective vaccines.
The fact that various industry leaders are approaching the final stage of vaccine development is quite necessary. Stoffels: “I believe the world will need a total of around 3 to 5 billion vaccine doses, so every developed vaccine counts in the drive to stop the COVID-19 pandemic quickly.”